The company manufactures and sells automotive suspension and fastening components, such as casting, machined, and forged parts, primarily for commercial vehicle manufacturers and the aftermarket.
The company operates in a highly competitive, commodity-like segment of the auto-ancillary industry. While it claims a leadership position, the financial metrics—specifically an average ROCE of 4.3% and negative net margins—contradict the existence of any durable competitive advantage or pricing power.
Capital allocation has been poor, characterized by reinvestment into a business that generates sub-cost-of-capital returns. The company recently resorted to a rights issue to fund working capital and debt repayment, indicating an inability to generate sufficient internal cash for growth.
The company's chronic inability to earn its cost of capital finally led to a liquidity trap. By relying on dilutive rights issues to fund basic operations rather than organic cash flow, the business eroded shareholder value until the 'CARE C' credit rating inevitably slipped toward default. As interest coverage remained razor-thin, the high promoter remuneration and related-party costs consumed what little remained of the operating surplus, leaving the firm unable to modernize or compete in a tightening auto-ancillary market.
RichFakir rates G S Auto International Ltd's business quality as poor — 14/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, G S Auto International Ltd is trading about 46% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on G S Auto International Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of G S Auto International Ltd's fair value is about ₹11 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →